CIRCULOGENE
Dr. Eric Thompson had years of experience managing and providing consulting services regarding biomarker research across a number of different organizations, including serving as Assistant Director of the Predictive Safety Testing Consortium (PSTC) at The Critical Path Institute. He has been involved in designing and enabling clinical use of molecular profiles for cancer patients. Dr. Thompson has extensive experience in the fields of pharmacology, toxicology, and molecular biology, and spearheaded the development of a proprietary evidence-based medicine engine. He is also responsible for working on business development efforts related to biomarker strategy and custom biopharma assay development. Prior to joining CIRCULOGENE, Dr. Thompson was a Paradigm Diagnostics founder and held the position of Vice President of Biomarker Research. Dr. Thompson has a Ph.D. in Pharmacology and Toxicology from the University of Arizona and did his Research Fellowship at the Mayo Clinic in Scottsdale.
This person is not in any offices
CIRCULOGENE
Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood in one week, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence.